Abstract

Inflammation is an important etiological factor of hypertensive renal damage. The effects of Yishen Pinggan Recipe (YPR) on urine microalbumin, histology, and NF-κB/P65, IκB-α, IL-1β, IL-6, and TNF-α in renal tissues were evaluated in SHR to explore the mechanism of its renal protection in hypertensive renal damage. The SBP of 12-week-old SHR was 192.41 ± 3.93 mmHg and DBP was 142.38 ± 5.79 mmHg. Without treatment, the 24-week-old SHRs' SBP was 196.96 ± 3.77 mmHg and DBP was 146.08 ± 4.82 mmHg. After the 12-week-old SHR were administered YPR for 12 weeks, the rats' SBP was 161.45 ± 7.57 mmHg and DBP was 117.21 ± 5.17 mmHg; YPR could lower blood pressure in SHR. And renal function damage was observed in 24-week-old SHR without treatment, manifested as urine protein and morphological changes which could be inhibited by YPR. In addition, YPR could reduce the expression of inflammatory cytokines (IL-1β, IL-6, and TNF-α) in kidneys. It could also inhibit the nuclear translocation of NF-κB p65 and degradation of IκB-α in renal cells, indicating that the NF-κB signaling pathway was inhibited by YPR. Finally, the study suggests that YPR could significantly improve the renal function in SHR. The mechanism could be attributed to its inhibition of renal NF-κB signaling pathway and inflammation.

Highlights

  • Kidney is one of the major target organs affected by hypertension

  • The effect of Yishen Pinggan Recipe (YPR) was weaker compared with angiotensin-converting enzyme inhibitors (ACEI) benazepril, it suggested that YPR could lower the blood pressure

  • The effect was similar to ACEI benazepril (Figures 1(a) and 1(b)), indicating that YPR was renally protective

Read more

Summary

Introduction

Kidney is one of the major target organs affected by hypertension. Forty-two percent of the primary hypertension patients not treated develop into kidney sclerosis, and about 10% die from renal failure [1, 2]. About 28% of endstage renal diseases are related to hypertensive renal damage. It is significant to prevent and treat the renal damage caused by hypertension. Angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), calcium-antagonists (CCB), and diuretic agents are employed to prevent and treat hypertension and its renal damage. The number of patients who developed into chronic renal dysfunction due to hypertensive renal damage is rising rapidly. It is urgent to explore new prevention and treatment methods

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call